In the present study we sought to improve the efficacy and safety of our Sca1+ PDGFB stem
cell gene therapy for osteoporosis in ovariectomized (OVX) mouse model. This therapy is …

In the present study we sought to improve the efficacy and safety of our Sca1+ PDGFB stem
cell gene therapy for osteoporosis in ovariectomized (OVX) mouse model. This therapy is …

Substantial advances have been made in the past two decades in the management of
osteoporosis. However, none of the current medications can eliminate the risk of fracture …

Osteoporotic fracture is the main complication of osteoporosis (OP) and accounts for millions
of injuries annually. Local intervention by intra-marrow injection has been a good option for …

A major problem in bone-wasting diseases such as osteoporosis is the loss of endosteal
bone that results in reduced bone strength and increased fracture risk. Recent advances in …

Induction of osteolytic bone disease in multiple myeloma (MM) is caused by activation of
osteoclastogenesis and suppression of osteoblastogenesis. Bone formation is reduced …

This study assessed the feasibility of using an ex vivo stem cell antigen-1–positive (Sca-1+)
cell–based systemic fibroblast growth factor-2 (FGF-2) gene therapy to promote endosteal …

Gene therapy for osteopenic conditions including osteoporosis is a potential alternative to
pharmacotherapy for cost effectiveness, long-term viability, and the ability to enhance bone …

Our previous work showed that a Sca-1+ cell-based FGF2 therapy was capable of promoting
robust increases in trabecular bone formation and connectivity on the endosteum of long …

Investigations based on mesenchymal stem cells (MSCs) for osteoporosis have attracted
attention recently. MSCs can be derived from various tissues, such as bone marrow …